套细胞淋巴瘤
胚泡
侵袭性淋巴瘤
医学
淋巴瘤
疾病
肿瘤科
临床试验
内科学
病理
癌症研究
免疫学
生物信息学
美罗华
生物
作者
Matthew R. Wilson,Aisling Barrett,Chan Y. Cheah,Toby A. Eyre
摘要
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma with a variable clinical course and historically poor prognosis. Management is challenging in part due to the heterogeneity of the disease course, with indolent and aggressive subtypes now well recognised. Indolent MCL is often characterised by a leukaemic presentation, SOX11 negativity and low proliferation index (Ki-67). Aggressive MCL is characterised by rapid onset widespread lymphadenopathy, extra-nodal involvement, blastoid or pleomorphic histology and high Ki-67. Tumour protein p53 (TP53) aberrations in aggressive MCL are recognised with clear negative impact on survival. Until recently, trials have not addressed these specific subtypes separately. With the increasing availability of targeted novel agents and cellular therapies, the treatment landscape is constantly evolving. In this review, we describe the clinical presentation, biological factors, and specific management considerations of both indolent and aggressive MCL and discuss current and potential future evidence which may help move to a more personalised approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI